We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+12.62%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$615M
AUM Growth
+$85.2M
Cap. Flow
+$34.9M
Cap. Flow %
5.67%
Top 10 Hldgs %
53.32%
Holding
366
New
100
Increased
78
Reduced
73
Closed
88

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$19.3M
2
ASND icon
Ascendis Pharma A/S
ASND
+$14.9M
3
ZURA icon
Zura Bio
ZURA
+$14.1M
4
AAM
AA Mission Acquisition Corp
AAM
+$10.1M
5
ZLAB icon
Zai Lab
ZLAB
+$9.65M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$25.2M
2
ROIV icon
Roivant Sciences
ROIV
+$12.8M
3
MRK icon
Merck
MRK
+$8.86M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$8.32M
5
QURE icon
uniQure
QURE
+$5.48M

Sector Composition

Rank Sector Weight
1 Healthcare 85.92%
2 Financials 3.35%
3 Communication Services 0.57%
4 Technology 0.47%
5 Utilities 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OABI icon
26
OmniAb
OABI
$299M
$5.66M 0.92%
1,337,302
+624,742
+88% +$2.7M
CGON icon
27
CG Oncology
CGON
$6.3B
$5.4M 0.88%
143,104
+130,254
+1,014% +$4.57M
CRNX icon
28
Crinetics Pharmaceuticals
CRNX
$8.91B
$4.52M 0.73%
88,425
+13,575
+18% +$700K
APLT
29
CALL
DELISTED
Applied Therapeutics
APLT
$4.51M 0.73%
+530,200
New +$3.12M
BBOT
30
BridgeBio Oncology
BBOT
$705M
$4.22M 0.69%
404,138
– –
XBI icon
31
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.94B
$3.95M 0.64%
+40,000
New +$3.93M
TECX
32
Tectonic Therapeutic
TECX
$554M
$3.85M 0.63%
127,159
-229,719
-64% -$4.2M
ITOS
33
DELISTED
iTeos Therapeutics
ITOS
$3.85M 0.63%
376,737
+316,737
+528% +$4.83M
ABSI icon
34
Absci
ABSI
$1.43B
$3.84M 0.62%
1,005,750
-692,779
-41% -$2.76M
EDR
35
DELISTED
Endeavor Group Holdings, Inc.
EDR
$3.51M 0.57%
122,807
+112,192
+1,057% +$3.09M
APGE icon
36
Apogee Therapeutics
APGE
$10.1B
$3.36M 0.55%
57,183
+16,308
+40% +$781K
DNTH icon
37
Dianthus Therapeutics
DNTH
$6.05B
$3.25M 0.53%
+118,738
New +$3.31M
SVRA icon
38
Savara
SVRA
$1.13B
$3.15M 0.51%
742,634
+79,036
+12% +$349K
DNLI icon
39
Denali Therapeutics
DNLI
$3.85B
$2.97M 0.48%
101,826
+63,826
+168% +$1.58M
GRCE
40
Grace Therapeutics
GRCE
$34.5M
$2.88M 0.47%
959,571
– –
QTTB icon
41
Q32 Bio
QTTB
$488M
$2.87M 0.47%
64,245
-92,259
-59% -$3.39M
PLRX icon
42
Pliant Therapeutics
PLRX
$65M
$2.76M 0.45%
246,128
+236,128
+2,361% +$2.95M
GERN icon
43
Geron
GERN
$1.02B
$2.53M 0.41%
557,159
+467,159
+519% +$2.12M
PVLA
44
Palvella Therapeutics
PVLA
$2.18B
$2.4M 0.39%
+144,641
New +$2.11M
VIR icon
45
Vir Biotechnology
VIR
$1.54B
$2.39M 0.39%
319,185
+209,185
+190% +$1.82M
NVO
46
PUT
Novo Nordisk
NVO
$197B
$2.38M 0.39%
+20,000
New +$2.67M
CLRB icon
47
Cellectar Biosciences
CLRB
$20M
$2.19M 0.36%
34,072
+11,336
+50% +$748K
ALKS icon
48
Alkermes
ALKS
$8.31B
$2.08M 0.34%
74,431
-122,146
-62% -$3.26M
SNDX icon
49
CALL
Syndax Pharmaceuticals
SNDX
$1.75B
$2.02M 0.33%
+105,000
New +$2.17M
RVMD icon
50
Revolution Medicines
RVMD
$41.8B
$2.01M 0.33%
+44,351
New +$1.93M
1
2
3 4 5

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

ADAR1 Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, ADAR1 Capital Management held 366 positions worth $615M, up 16% from $530M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

ADAR1 Capital Management deployed $34.9M of net new capital in Q3 2024, opening 100 new positions and adding to 78 existing holdings. Its largest new stake was Zura Bio: 3,770,649 shares worth $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 80% a quarter earlier, followed by Financials and Communication Services.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $25.2M trimmed.

  • ADAR1 Capital Management's largest Q3 2024 buy was Zura Bio: 3,770,649 shares worth $15.3M.
  • ADAR1 Capital Management added most to Immunovant in Q3 2024, an estimated $19.3M increase.
  • ADAR1 Capital Management's biggest Q3 2024 reduction was Protagonist Therapeutics, cutting an estimated $25.2M.
  • ADAR1 Capital Management fully exited uniQure in Q3 2024, selling an estimated $5.48M.
  • ADAR1 Capital Management's ten largest holdings make up 53% of its $615M portfolio in Q3 2024.
  • ADAR1 Capital Management opened 100 new positions and closed 88 in Q3 2024.
  • ADAR1 Capital Management's portfolio value rose 16% quarter-over-quarter to $615M.

Based on ADAR1 Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.